{
    "clinical_study": {
        "@rank": "62214", 
        "arm_group": [
            {
                "arm_group_label": "Glyburide", 
                "arm_group_type": "Active Comparator", 
                "description": "Glyburide 2,5 mg"
            }, 
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Metformin 500mg bid"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine the efficacy of oral treatment with glyburide and\n      metformin controlling excessive fetal growth in women with gestational diabetes, using\n      insulin as a ransom on no response to oral treatment .\n\n      It is randomized with women who seek care at the Outpatient Diabetes in Pregnancy in our\n      hospital trial Eligible women between 18 - 45anos diagnosed with gestational diabetes ,\n      according to the WHO criteria , ratified the public network for prenatal care at the Clinic\n      for Diabetes and Pregnancy HCPA .\n\n      Women with singleton pregnancy and gestational age not exceeding 30 weeks at the time of\n      enrollment.\n\n      Pregnant women with indication for pharmacological treatment will be invited to\n      randomization to use of oral , glyburide or metformin antidiabetic .\n\n      At regular intervals of 2 - 3 weeks fetal growth will be measured with obstetric\n      ultrasonography , until birth.\n\n      The primary outcomes will be :\n\n      ( 1 ) weight and gestational age at birth and the index of large for gestational age fetuses\n      ( \u2265 90th percentile for gestational age ) ( 2 ) the use of insulin to achieve glycemic\n      targets according to fetal growth , as an indirect measure of the inefficiency of oral\n      medications ."
        }, 
        "brief_title": "Oral Antidiabetic Agents in Pregnancy", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gestational Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes, Gestational"
            ]
        }, 
        "detailed_description": {
            "textblock": "The procedures for monitoring metabolic and obstetrical control , assessments of fetal well\n      -being and indications for interruption are usually adopted in the Outpatient Diabetes and\n      Pregnancy of the institution.\n\n      - Patients will be followed since their first appointment in our hospital, around the 20th\n      week of pregnancy- until 8 weeks after labor and delivery. That being said, patients will be\n      followed by an average of 28 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible women between 18-45 years diagnosed with gestational diabetes, according to\n             the WHO criteria (19), ratified the public network for prenatal care at the Clinic\n             for Diabetes and Pregnancy.\n\n          -  Women with singleton pregnancy and gestational age not exceeding 30 weeks at the time\n             of enrollment, calculated from ultrasound (U.S.) Obstetric performed before the 20th\n             week of pregnancy will be enrolled.\n\n        Exclusion Criteria:\n\n          -  Women who present enrollment in the diagnosis of chronic hypertension, heart disease\n             or chronic lung disease intrauterine restricted or preterm labor, growth, or even\n             chronic diarrhea will be excluded"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091336", 
            "org_study_id": "OAGM-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin", 
                "description": "patients treatment", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage, Glifage"
            }, 
            {
                "arm_group_label": "Glyburide", 
                "description": "patients treatment", 
                "intervention_name": "Glyburide", 
                "intervention_type": "Drug", 
                "other_name": "Glibenclamida, Glucovance"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glyburide", 
                "Hypoglycemic Agents", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "gestational diabetes", 
            "metformin", 
            "glyburide", 
            "fetal growth", 
            "capillar glucose"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Porto Alegre", 
                    "country": "Brazil", 
                    "state": "RS", 
                    "zip": "90035-903"
                }, 
                "name": "Hospital de Cl\u00ednicas de Porto Alegre"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Oral Antidiabetic Agents on Gestational Diabetes: Modulating Effect on Fetal Growth - a Clinical Randomized Trial", 
        "other_outcome": [
            {
                "description": "medications will be suspended if patients present with repeated hypoglycaemia", 
                "measure": "hypoglycaemia", 
                "safety_issue": "No", 
                "time_frame": "up to 9 months"
            }, 
            {
                "measure": "maternal weight gain", 
                "safety_issue": "No", 
                "time_frame": "up to 9 months"
            }, 
            {
                "measure": "neonatal 5th minute apgar", 
                "safety_issue": "No", 
                "time_frame": "5 minutes after birth"
            }, 
            {
                "measure": "neonatal hypoglycaemia and respiratory distress", 
                "safety_issue": "No", 
                "time_frame": "48 hours after birth"
            }, 
            {
                "measure": "neonatal need of intensive care", 
                "safety_issue": "No", 
                "time_frame": "48 hours after birth"
            }, 
            {
                "measure": "need of c section", 
                "safety_issue": "No", 
                "time_frame": "day of birth"
            }
        ], 
        "overall_contact": {
            "email": "maluopp@gmail.com", 
            "last_name": "Maria Lucia R Oppermann, PhD", 
            "phone": "55 51 33598117"
        }, 
        "overall_contact_backup": {
            "email": "vanessagenro@gmail.com", 
            "last_name": "Vanessa K Genro, PhD", 
            "phone": "55 51 81313734"
        }, 
        "overall_official": [
            {
                "affiliation": "HCPA-UFRGS", 
                "last_name": "Maria Lucia R Oppermann, PhD Prf", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "HCPA", 
                "last_name": "Vanessa K Genro, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "fetal growth will be assessed every 3 weeks by obstetric ultrasound during pregnancy until delivery", 
            "measure": "fetal growth", 
            "safety_issue": "No", 
            "time_frame": "up to 9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "every week patients will have one whole day in the hospital to monitor capillar glucose levels", 
            "measure": "insulin requirements to achieve glucose targets", 
            "safety_issue": "No", 
            "time_frame": "up to 9 months"
        }, 
        "source": "Hospital de Clinicas de Porto Alegre", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital de Clinicas de Porto Alegre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}